Introduction

35
Ischemic stroke represents one of the most frequent causes of death and leading 36 cause of disability worldwide [1] . In the absence of any effective neuroprotective 37 principle, thrombolytic or mechanical removal of the occlusion remains the only 38 current therapeutic option [2] . In 11% of the mechanically re-canalysed patients, 39 however, serious complications occur including new emboli formation, vasospasm, 40 intracranial haemorrhage and stent dislocation or occlusion [3] . Similarly, 41 thrombolysis using tissue plasminogen activator (rt-PA) correlates with an early 42 opening of the blood-brain barrier (BBB) 4 , which may lead to pathologic processes 43 such as edema and hemorrhage transformation 4 under control of the Tie2 promoter (Fig 1A-B) . The Tie2 promoter physiologically 70 regulates endothelial and hematopoietic gene expression in human cells [12, 13] . 71 Therefore, using this promoter we expected our transgenic mouse model to mimic 72 physiological human NOX5 expression, both in endothelial and white blood cells. 73 We HBMECs to 6h of hypoxia followed by 24h of re-oxygenation and assessment of cell Eagle medium (DMEM; Sigma-Aldrich, Germany) for 1h at 37°C. To remove myelin, 
Brain infarct volume measurements
392
The ischemic lesion was measured 24 hours after tMCAO using TTC staining [33] . 
Evaluation of infarct size in heart
469
After the hemodynamic measurements at day 28, the heart was excised and the 470 atria were removed. The ventricles were cut transversally at 3 mm from the apex. closed with a 4-0 polysorb suture and the mouse was allowed to recover. 
